Rajiv Muradia - Predictmedix VP Technology
| PMEDF Stock | USD 0.01 0 10.00% |
Insider
Rajiv Muradia is VP Technology of Predictmedix
| Phone | 778 229 4319 |
| Web | https://www.predictmedix.com |
Predictmedix Management Efficiency
The company has return on total asset (ROA) of (0.805) % which means that it has lost $0.805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9957) %, meaning that it generated substantial loss on money invested by shareholders. Predictmedix's management efficiency ratios could be used to measure how well Predictmedix manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ehab Esmail | Orthofix Medical | 52 | |
| Jesse Selnick | Sight Sciences | N/A | |
| Anthony Semedo | Artivion | 69 | |
| Jean Holloway | Artivion | 63 | |
| Krissy Wright | Paragon 28 | N/A | |
| Diane Biagianti | Glaukos Corp | 64 | |
| Lindsey Little | LivaNova PLC | N/A | |
| Brendan Shook | Paragon 28 | N/A | |
| Marshall Stanton | Artivion | 64 | |
| Jon Salveson | Artivion | 56 | |
| John Ordway | Sight Sciences | N/A | |
| Charles III | Anika Therapeutics | N/A | |
| S Mansbach | Avanos Medical | N/A | |
| BA Chemistry | Orthofix Medical | 63 | |
| David Colleran | Anika Therapeutics | 52 | |
| Sam Park | Sight Sciences | 63 | |
| Jason Edie | Paragon 28 | N/A | |
| Jeremy Hayden | Sight Sciences | 54 | |
| Barbara Schwarzentraub | CONMED | 53 | |
| John Liu | Sight Sciences | N/A | |
| B Johnson | Paragon 28 | 68 | |
Management Performance
| Return On Equity | -2.0 | |||
| Return On Asset | -0.8 |
Predictmedix Leadership Team
Elected by the shareholders, the Predictmedix's board of directors comprises two types of representatives: Predictmedix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Predictmedix. The board's role is to monitor Predictmedix's management team and ensure that shareholders' interests are well served. Predictmedix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Predictmedix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Guru Seghal, Managing Operations | ||
| Rajiv Muradia, VP Technology | ||
| Sheldon Kales, CEO Pres | ||
| Rahul BSc, COO Director |
Predictmedix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Predictmedix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0 | |||
| Return On Asset | -0.8 | |||
| Operating Margin | (24.76) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 122.05 M | |||
| Shares Owned By Insiders | 31.02 % | |||
| Price To Book | 7.28 X | |||
| Price To Sales | 30.93 X | |||
| Revenue | 134.82 K | |||
| Gross Profit | 84.82 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Predictmedix Pink Sheet
Predictmedix financial ratios help investors to determine whether Predictmedix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Predictmedix with respect to the benefits of owning Predictmedix security.